GB201222563D0 - Cancer treatment - Google Patents
Cancer treatmentInfo
- Publication number
- GB201222563D0 GB201222563D0 GBGB1222563.7A GB201222563A GB201222563D0 GB 201222563 D0 GB201222563 D0 GB 201222563D0 GB 201222563 A GB201222563 A GB 201222563A GB 201222563 D0 GB201222563 D0 GB 201222563D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1222563.7A GB2508890A (en) | 2012-12-14 | 2012-12-14 | Anti-cancer agent and mitochondrial division inhibitor combination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1222563.7A GB2508890A (en) | 2012-12-14 | 2012-12-14 | Anti-cancer agent and mitochondrial division inhibitor combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201222563D0 true GB201222563D0 (en) | 2013-01-30 |
| GB2508890A GB2508890A (en) | 2014-06-18 |
Family
ID=47630732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1222563.7A Withdrawn GB2508890A (en) | 2012-12-14 | 2012-12-14 | Anti-cancer agent and mitochondrial division inhibitor combination |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2508890A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2976632A1 (en) * | 2015-02-13 | 2016-08-18 | Stealth Biotherapeutics Corp | Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080032940A1 (en) * | 2006-08-07 | 2008-02-07 | Balaraman Kalyanaraman | Methods for reducing anthracycline-induced toxicity |
| US8759097B2 (en) * | 2011-04-19 | 2014-06-24 | University of Pittsburgh—of the Commonwealth System of Higher Eduction | Inhibition of dynamin related protein 1 to promote cell death |
| EP2718277A4 (en) * | 2011-06-06 | 2015-02-11 | Cardero Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL TOXICITY |
-
2012
- 2012-12-14 GB GB1222563.7A patent/GB2508890A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2508890A (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| IL272206A (en) | Combination therapy for treating cancer | |
| PL3967315T3 (en) | Akkermansia muciniphila for treating cancer | |
| PL2707030T3 (en) | Cancer treatments | |
| GB201217439D0 (en) | Combination therapy | |
| EP2903644A4 (en) | Treatment of cancer | |
| IL222958A0 (en) | Cancer treatment | |
| GB201217892D0 (en) | Treatment of cancer | |
| GB201207305D0 (en) | Therapy | |
| SI2892925T1 (en) | Combination treatment of cancer | |
| EP2864362A4 (en) | Anticancer treatment | |
| DK2872176T3 (en) | Cancer treatment | |
| EP2934500A4 (en) | Combination therapy for cancer | |
| PL2855475T3 (en) | Alpha-carbolines for the treatment of cancer | |
| EP2879707A4 (en) | Combination therapy | |
| GB201106630D0 (en) | Cancer therapy | |
| GB201222563D0 (en) | Cancer treatment | |
| GB201217890D0 (en) | Treatment of cancer | |
| IL239231A0 (en) | Combination therapy for cancer | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| GB201208296D0 (en) | Treatment of cancer | |
| GB201211135D0 (en) | Treatment | |
| GB201208690D0 (en) | Treatment | |
| GB201202550D0 (en) | Non Invasive Cancer Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |